What do we know?, page-4

Stayso, I think bit of an emotional over- reaction!
Read my post again objectively, nowhere have I said it’s a waste of time. I simply stated a fact that (unless RBx is privy to confidential trial data) you can’t possibly know that there was (or will be) no adverse reaction in the first patient dosed. All the Nox announcement said was first patient enrolled and treated.
and second, the other obvious fact that the trial isn’t designed to prove veyondas efficacy , it’s primarily a safety dose finding study and there’s no control arm right?
If other therapies with proven benefit are allowed in the trial pts eg steroids, then in non controlled trial it becomes hard to prove any positive outcome was definitely due to veyonda.
Even Nox CEO/CMO would acknowledge that.
just science.